Xenon Pharmaceuticals Inc.

XENE · NasdaqGM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders0.1%

Institutions107.6%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$7.50M	–	$9.43M	$18.44M	$32.17M	–	–	$311000	$1.80M	$15.58M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$373.07M	-$279.30M	-$129.14M	-$78.99M	-$31.30M	-$42.82M	-$38.02M	-$32.58M	-$24.82M	-$9.36M
Operating income as a percentage of revenue.	-4974.3%	–	-1368.9%	-428.4%	-97.3%	–	–	-10474.3%	-1376.4%	-60.1%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$345.91M	-$234.33M	-$125.37M	-$78.88M	-$28.84M	-$41.59M	-$34.50M	-$30.70M	-$23.00M	-$15.75M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-4.36	$-3.01	$-2.00	$-1.77	$-0.81	$-1.00	$-1.00	$-1.00	$-1.00	$-1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-4.36	$-3.01	$-2.00	–	–	–	$-1.00	$-1.00	$-1.00	$-1.00

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$199.16M	$142.71M	$57.24M	$175.69M	$45.01M	$24.75M	$67.75M	$20.49M	$17.09M	$17.84M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$633.16M	$798.14M	$754.15M	$572.01M	–	$147.70M	$122.43M	$46.12M	$67.49M	$63.95M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	$15.54M	$15.01M	$6.80M	–	–
Everything the company owes — debt, unpaid bills, and other obligations.	$51.40M	$43.24M	$32.65M	$21.97M	–	$55.72M	$19.13M	$10.19M	$3.59M	$2.92M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$581.76M	$754.90M	$721.50M	–	–	–	$103.30M	$35.93M	$63.90M	-$990000

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$279.12M	-$181.39M	-$98.43M	-$69.50M	-$48.12M	-$4.63M	-$34.72M	-$28.73M	-$19.57M	-$18.10M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$799000	$3.08M	$2.89M	$2.05M	$2.64M	$1.24M	$507000	$315000	$279000	$551000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$279.92M	-$184.46M	-$101.32M	-$71.55M	-$50.76M	-$5.87M	-$35.23M	-$29.04M	-$19.85M	-$18.65M

	You	Peer avg
P/E	–	6.8
Revenue Growth	–	-54.1%
ROE	-43.6%	4.2%

Xenon Pharmaceuticals Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison